Dilip Shanghvi’s daughter Vidhi to head consumer healthcare business at Sun Pharma

no thumb

Dilip Shanghvi’s daughter Vidhi to head consumer healthcare business at Sun Pharma Sun Pharmaceutical Industries, India’s largest drug maker, may be struggling to rebuild its generic business, but billionaire founder Dilip Shanghvi is putting in place a succession plan, handing over some of the reins of the company to his children.

Three years after son Aalok Shanghvi was inducted as emerging markets head of Sun Pharma, the company introduced daughter Vidhi Salgaocar as head of the Consumer Healthcare business, a separate division, on Monday. The announcement was made at the launch of its over-the-counter anti-fungal product ABZORB.

A graduate in economics from the Wharton School of the University of Pennsylvania, Salgaocar joined Sun Pharma in 2012. Before officially taking charge as head of the consumer division she led the marketing function of the India business.

Salgaocar played a “major role in developing the nutrition business of Sun Pharma and spearheaded the company’s strategy to enter the nutrition space,” said a company official who did not wish to be identified.

Sun Pharma Consumer Healthcare also launched a marketing campaign comprising TV, print and digital for ABZORB.

“Fungal infections are a common occurrence and are often left untreated because of the associated social stigma,” Salgaocar said in a statement. The marketing campaign will raise consumer awareness regarding fungal infections and empower them to treat the infection, she said.

An email sent to Sun Pharma about the growth of Sun Pharma’s consumer division and the company’s broader succession plan remained unanswered.

India’s consumer healthcare business is estimated to expand to $280 billion from about $100 billion currently. In India, traditional drug makers appear to be entering the space after building their generic drugs business.

Piramal Enterprises acquired brands from companies including Pfizer to build its over-the-counter business. Global consumer companies, too, are betting on India’s consumer market to expand their business. Procter & Gamble acquired the India consumer business of German drug maker Merck for Rs 1,200 crore as part of a global deal in April.

Sun Pharma’s consumer healthcare division has five key brands including Revital H and Volini, according to the company website. Sun Pharma CHC said its sales and distribution strategy involves penetrating up to Class II towns directly and smaller towns through the ‘hub and spoke’ model.

“We pursue a differentiated sales and distribution strategy of engaging FMCG/OTC distributors for our OTC products. The distribution infrastructure continues to grow, with about 2,500+ distributors and sales representatives covering 100K+ outlets across the country,” according to its website.

Source link

The author

Leave a Response